PDCD1 and melanoma: Preliminary results of one such clinical trial demonstrates striking efficacy of LAG3+PD1-blockade (BMS-986016 and nivolumab, respectively) for treatment of advanced melanoma patients whom PD1/PD-L1-blockade previously failed (16% objective response rate and 45% disease control rate) [104].